Status:
COMPLETED
Treatment of Hepatitis C in Psychiatric Patients
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Ludwig-Maximilians - University of Munich
Conditions:
Mental Disorders
Drug Addiction
Eligibility:
All Genders
18-70 years
Brief Summary
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of Interferon-alpha in patients with chronic hepatitis C. The investigators aim is/was to get prospectiv...
Detailed Description
Patients from the Munich University outpatient department of psychiatry or gastroenterology as well as inpatients with elevated transaminases were tested for HCV-infection and considered for our trial...
Eligibility Criteria
Inclusion
- Medical inclusion criteria were a detectable serum HCV-RNA level in a PCR-based assay (AMPLICOR®, Roche Diagnostics, Branchburg, NJ) for more than 6 months and an elevated alanine aminotransferase (ALT \> 30 U/L, normal \<24 U/L).
Exclusion
- General exclusion criteria were the presence of other liver disease
- Child B or C cirrhosis
- Severe cardiac or neurological disease
- Co-infection with hepatitis B or HIV
- Hepatocellular carcinoma evaluated by ultrasound and alpha-fetoprotein
- Autoimmune disorders
- Neutrophil count below 1500 per cubic millimetre
- Platelet count below 75000 per cubic millimetre
Key Trial Info
Start Date :
August 1 1999
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2002
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00751426
Start Date
August 1 1999
End Date
May 1 2002
Last Update
September 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry
Munich, Germany, 80336